ezogabine has been researched along with sb 705498 in 1 studies
Studies (ezogabine) | Trials (ezogabine) | Recent Studies (post-2010) (ezogabine) | Studies (sb 705498) | Trials (sb 705498) | Recent Studies (post-2010) (sb 705498) |
---|---|---|---|---|---|
383 | 26 | 241 | 35 | 7 | 24 |
Protein | Taxonomy | ezogabine (IC50) | sb 705498 (IC50) |
---|---|---|---|
Transient receptor potential cation channel subfamily V member 1 | Rattus norvegicus (Norway rat) | 0.032 | |
Transient receptor potential cation channel subfamily M member 8 | Homo sapiens (human) | 1.6 | |
Transient receptor potential cation channel subfamily V member 1 | Homo sapiens (human) | 0.0546 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Gao, J; Guo, Y; Hu, X; Huang, H; Jin, Z; Li, Z; Liu, Z; Wang, K; Wang, Y; Zhang, L; Zhong, Y; Zong, X | 1 |
1 other study(ies) available for ezogabine and sb 705498
Article | Year |
---|---|
Optimization of 4-arylthiophene-3-carboxylic acid derivatives as inhibitors of ANO1: Lead optimization studies toward their analgesic efficacy for inflammatory pain.
Topics: Analgesics; Animals; Anoctamin-1; Carboxylic Acids; HEK293 Cells; Humans; Hyperalgesia; Mice; Neoplasm Proteins; Pain | 2022 |